Since the organized takedown of IPIX in the past 5 years, the criminals have come up with many false narratives on why IPIX SP continued to go down. Many of the attacks targeted Leo in addition to their favorite FUD blaming Aspire selling and more recently the selling from the big bad MFO. The criminals have spewed every theory except for the truth which is that IPIX has been the target of a criminal illegal attack that has been well funded by a hedge fund using fake spoofed volume by crooked MM’s, paid hard and soft bashers working the SMBs and the heavy use of illegal Naked Short Selling (NSS) to continue the compression of IPIX SP with the intent to put IPIX out of business.
The 7/7/20 PR stated that all preferred shares and warrants previously allotted have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020. On Friday 7/10/20 a 13G form was filed stating that a MFO owned more than 5% of the 328M outstanding shares. Separately IPIX filed a Shelf Registration for up to $60M.
So now that IPIX has $6M in cash and basically a $60M line of credit, what will the paid bashers new false narrative be? How about stating that the entire U.S. government and Big Pharma are so corrupt that little IPIX will never get a government grant on its own even though Brilacidin is the most effective CV19 treatment to combat a worldwide pandemic that kills thousands of people daily? I hate to be harsh but if any investor believes this garbage they deserve to lose their shares cheaply and should never have invested in biotech in the first place.
Well it has been a whole month since the 6/11/20 PR stating that the RBL was collaborating with IPIX on a federal grant application. Has anyone thought about what a government agency might want to have answered before awarding and releasing a large grant and sponsoring a CV19 human trial? It might be nice to know that the drug is manufactured in ample supply and formulated for the delivery mechanism to be used in the trial. It might also be nice to know the level and frequency of dosing. Does anyone remember the George Mason University news release stating that they were doing Brilacidin testing for $35k starting in May with an August completion date? Did anyone notice that the items listed on the GMU release were the same items that IPIX PRed on 4/27/20? Did anyone realize that Leo was getting valuable advanced testing for a paltry price that would be extremely valuable for structuring human trials? Here are the items regarding advanced testing to be performed by the RBL from the 4/27/20 IPIX release:
• Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Result was 97% reduction in human cell viral load per 6/17/20 PR
• Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line per 6/17/20 PR
• Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity)
This is THE DEFINITION of the Selectivity Index which is the next planned testing per the 7/7/20 PR
• Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
• Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity.
As you can see from above, the advanced testing PRed 4/27/20 has either been completed or is soon to be complete. Also note with $6M in cash Leo can execute per the 6/17/20 PR: “The Company is in the process of manufacturing Brilacidin for intravenous (IV) dosing and will be seeking FDA guidance for a planned COVID-19 clinical study.” And on 7/7/20 “Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.” And ““The world continues to suffer from the coronavirus pandemic, both in lives lost and economic devastation. We steadfastly believe that Brilacidin could play a significant role in treating this highly contagious and deadly virus.”
Note that all the above activity is related to the GMU RBL. Let’s not forget the PHRI who signed a MTA on 5/5/20 and announced on 5/26/20 ONLY 3 WEEKS later that they had successfully tested Brilacidin on human kidney tissue with up to an 85% viral reduction. We could very well hear some other breakthrough or funding opportunity coming from the PHRI at any time. Both the RBL and the PHRI will be independently authoring peer review articles on Brilacidin for CV19.
IMO IPIX is advancing Brilacidin for CV19 in a very aggressive and structured manner. IMO IPIX does NOT need BP to advance Brilacidin for CV19. The criminal bashers will need to come up with some new FUD that unfortunately for them will be easy to refute as milestones are met. Investors should experience a very successful and profitable summer as grant funding, peer review articles and human CV19 FDA trials are implemented. The world needs an effective CV19 treatment and as Leo has stated, Brilacidin could very well become the Gold Standard.
The 7/7/20 PR stated that all preferred shares and warrants previously allotted have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020. On Friday 7/10/20 a 13G form was filed stating that a MFO owned more than 5% of the 328M outstanding shares. Separately IPIX filed a Shelf Registration for up to $60M.
So now that IPIX has $6M in cash and basically a $60M line of credit, what will the paid bashers new false narrative be? How about stating that the entire U.S. government and Big Pharma are so corrupt that little IPIX will never get a government grant on its own even though Brilacidin is the most effective CV19 treatment to combat a worldwide pandemic that kills thousands of people daily? I hate to be harsh but if any investor believes this garbage they deserve to lose their shares cheaply and should never have invested in biotech in the first place.
Well it has been a whole month since the 6/11/20 PR stating that the RBL was collaborating with IPIX on a federal grant application. Has anyone thought about what a government agency might want to have answered before awarding and releasing a large grant and sponsoring a CV19 human trial? It might be nice to know that the drug is manufactured in ample supply and formulated for the delivery mechanism to be used in the trial. It might also be nice to know the level and frequency of dosing. Does anyone remember the George Mason University news release stating that they were doing Brilacidin testing for $35k starting in May with an August completion date? Did anyone notice that the items listed on the GMU release were the same items that IPIX PRed on 4/27/20? Did anyone realize that Leo was getting valuable advanced testing for a paltry price that would be extremely valuable for structuring human trials? Here are the items regarding advanced testing to be performed by the RBL from the 4/27/20 IPIX release:
• Testing Brilacidin’s direct virucidal activity on SARS-CoV-2 in human lung epithelial cells (by preincubating the novel coronavirus with Brilacidin at varying concentrations and times of incubation);
Result was 97% reduction in human cell viral load per 6/17/20 PR
• Obtaining the in vitro concentration of Brilacidin that gives half-maximal response, the EC50 value, in lung epithelial cells;
Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line per 6/17/20 PR
• Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity)
This is THE DEFINITION of the Selectivity Index which is the next planned testing per the 7/7/20 PR
• Evaluating time-to-treatment windows as a post-exposure therapeutic (by introducing Brilacidin at 4, 8, and 16 hours post-initial infection, with virus cultures carried forward up to 48 hours);
• Exploring if Brilacidin has synergistic properties with other small molecules that have antiviral activity.
As you can see from above, the advanced testing PRed 4/27/20 has either been completed or is soon to be complete. Also note with $6M in cash Leo can execute per the 6/17/20 PR: “The Company is in the process of manufacturing Brilacidin for intravenous (IV) dosing and will be seeking FDA guidance for a planned COVID-19 clinical study.” And on 7/7/20 “Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.” And ““The world continues to suffer from the coronavirus pandemic, both in lives lost and economic devastation. We steadfastly believe that Brilacidin could play a significant role in treating this highly contagious and deadly virus.”
Note that all the above activity is related to the GMU RBL. Let’s not forget the PHRI who signed a MTA on 5/5/20 and announced on 5/26/20 ONLY 3 WEEKS later that they had successfully tested Brilacidin on human kidney tissue with up to an 85% viral reduction. We could very well hear some other breakthrough or funding opportunity coming from the PHRI at any time. Both the RBL and the PHRI will be independently authoring peer review articles on Brilacidin for CV19.
IMO IPIX is advancing Brilacidin for CV19 in a very aggressive and structured manner. IMO IPIX does NOT need BP to advance Brilacidin for CV19. The criminal bashers will need to come up with some new FUD that unfortunately for them will be easy to refute as milestones are met. Investors should experience a very successful and profitable summer as grant funding, peer review articles and human CV19 FDA trials are implemented. The world needs an effective CV19 treatment and as Leo has stated, Brilacidin could very well become the Gold Standard.
24
